Hagberg K, Brodtkorb T-H. Patient-reported benefits of bone-anchored transfemoral prostheses as assessed by MedTech20 ©: a general outcome measure for medical products. Prosthet Orthot Int. 2021 Aug 1;45(4):355-61.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Normann E, Olsson A, Brodtkorb T. Modular socket system versus traditionally laminated socket: a cost analysis. Prosthet Orthot Int. 2011 Mar;35(1):76-80.
Ramstrand N, Brodtkorb T. Considerations for developing an evidenced-based practice in orthotics and prosthetics. Prosthet Orthot Int. 2008;32(1):93-102.
Pring CM, Skelding-Millar L, Goodall RJ. Expectant treatment or cholecystectomy after endoscopic retrograde cholangiopancreatography for choledocholithiasis in patients over 80 years old? Surg Endosc. 2005 Mar;19(3):357-60.